PRRT With 177Lu-Edotreotide Improves Outcomes vs Everolimus in Metastatic GEP-NETs: With Jonathan R. Strosberg, MD

Welcome to OncLive On Air^®!

OncLive On Air is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

_____

In today’s episode, the discussion features Jonathan R. Strosberg, MD, a professor and leader in the Neuroendocrine Tumor Division and the Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in Tampa, Florida, who reviewed the clinical implications of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide (ITM-11) for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), drawing on efficacy and safety findings from the phase 3 COMPETE trial (NCT03049189).

In our exclusive interview, Dr Strosberg contextualized 177Lu-edotreotide as a PRRT approach that is mechanistically similar to lutetium Lu 177 dotatate (Lutathera) but uses a different somatostatin analog vector. He also emphasized the relevance of COMPETE as a head-to-head comparison of lutetium-based PRRT vs an active standard option everolimus (Afinitor) in this setting. He summarized key efficacy signals, including an improvement in progression-free survival and higher response rates with PRRT vs everolimus, and discussed subgroup trends by grade, primary site, and line of therapy. He also highlighted practical takeaways relevant to real-word clinical practice.

_____

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.